sb 202190 has been researched along with sulfasalazine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Muthusamy, V; Piva, TJ | 1 |
2 other study(ies) available for sb 202190 and sulfasalazine
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
UVB-stimulated TNFα release from human melanocyte and melanoma cells is mediated by p38 MAPK.
Topics: Anisomycin; Anthracenes; Cell Line, Tumor; Cell Survival; Humans; Imidazoles; Interleukin-1alpha; MAP Kinase Signaling System; Melanocytes; Melanoma; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase 9; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Processing, Post-Translational; Pyridines; Sulfasalazine; Tumor Necrosis Factor-alpha | 2013 |